Balchem (NASDAQ:BCPC - Get Free Report) released its earnings results on Friday. The basic materials company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.11 by ($0.08), Zacks reports. The business had revenue of $240.00 million for the quarter, compared to the consensus estimate of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%.
Balchem Trading Up 4.8 %
BCPC traded up $8.02 during trading on Tuesday, hitting $173.59. 221,830 shares of the stock traded hands, compared to its average volume of 130,512. The firm has a 50-day moving average of $161.98 and a 200 day moving average of $169.37. Balchem has a 12-month low of $137.69 and a 12-month high of $186.03. The firm has a market capitalization of $5.64 billion, a P/E ratio of 44.17, a price-to-earnings-growth ratio of 4.41 and a beta of 0.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16.
Balchem Increases Dividend
The company also recently declared an annual dividend, which was paid on Friday, January 17th. Investors of record on Thursday, December 26th were issued a dividend of $0.87 per share. This is a positive change from Balchem's previous annual dividend of $0.79. This represents a yield of 0.4%. The ex-dividend date of this dividend was Thursday, December 26th. Balchem's dividend payout ratio is currently 22.14%.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on BCPC shares. HC Wainwright reaffirmed a "buy" rating and set a $190.00 price objective on shares of Balchem in a research note on Monday. StockNews.com upgraded Balchem from a "hold" rating to a "buy" rating in a research report on Monday, October 28th.
Get Our Latest Report on BCPC
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Articles
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
